drugset
drugset / Trial / NCT00904449

Open Label Assessment of Long-Term Safety and Utility

NCT00904449 ↗

Phase 3 Completed 24 enrolled Endo USA Inc., a Keenova Therapeutics Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to monitor the long-term analgesic effectiveness, safety, and utility of oxymorphone ER for the relief of moderate to severe pain due to cancer.

Timeline

Start
2001-04
Primary completion
2002-12
Completion
2002-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymorphone Small molecule 10 mg Oral
Subject Oxymorphone Small molecule 20 mg Oral
Subject Oxymorphone Small molecule 40 mg Oral

Indications

No indication recorded.